查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1506483

心房顫動 - 市場考察，流行病學，市場預測(2034年)

Atrial Fibrillation - Market Insight, Epidemiology, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

本報告提供心房顫動的主要7市場(美國，德國，西班牙，義大利，法國，英國，日本)調查分析，提供各地區市場規模，目前治療方法，未滿足需求，新治療方法等資訊。

目錄

第1章 重要考察

第2章 心房顫動的摘要整理

第3章 心房顫動相關競爭資訊分析

第4章 心房顫動:市場概要

  • 心房顫動的整體市場佔有率的分佈(2020年)
  • 心房顫動的整體市場佔有率的分佈(2034年)

第5章 心房顫動:疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第6章 病人歷程

第7章 心房顫動的流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與根據:主要7市場
  • 流行病學情勢:主要7市場
    • 主要7市場心房顫動的流行病學情勢(2020年～2034年)
  • 美國的流行病學
    • 美國的心房顫動的流行病學情勢(2020年～2034年)
  • 歐洲5個國家的流行病學:各國
    • 德國的流行病學
    • 法國的流行病學
    • 義大利的流行病學
    • 西班牙的流行病學
    • 英國的流行病學
    • 日本的流行病學

第8章 治療流程，目前治療，醫療行為

  • 心房顫動的治療和管理
  • 心房顫動的治療流程

第9章 未滿足需求

第10章 心房顫動治療主要的評估項目

第11章 已上市的產品

第12章 新治療方法

第13章 心房顫動:主要7市場分析

  • 主要調查結果
  • 主要7市場心房顫動的市場規模
  • 主要7市場心房顫動的市場規模:各治療法

第14章 屬性分析

第15章 主要7市場:市場預測

  • 美國:市場規模
    • 美國的心房顫動的整體市場規模
    • 美國的心房顫動的市場規模:各治療法
  • 歐洲5個國家:市場規模及預測
  • 德國的市場規模
    • 德國的心房顫動的整體市場規模
    • 德國的心房顫動的市場規模:各治療法
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
    • 英國的心房顫動的整體市場規模
    • 英國的心房顫動的市場規模:各治療法
  • 日本市場預測
    • 日本的市場規模

第16章 心房顫動的就醫與給付概要

第17章 KOL的見解

第18章 推動市場要素

第19章 市場障礙

第20章 附錄

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

Product Code: DIMI0254

DelveInsight's "Atrial Fibrillation - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atrial Fibrillation market report provides current treatment practices, emerging drugs, Atrial Fibrillation market share of the individual therapies, current and forecasted Atrial Fibrillation market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Atrial Fibrillation treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2020-2034

Atrial Fibrillation Disease Understanding and Treatment Algorithm

The DelveInsight Atrial Fibrillation market report gives a thorough understanding of the Atrial Fibrillation by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Atrial Fibrillation.

Treatment

It covers the details of conventional and current medical therapies available in the Atrial Fibrillation market for the treatment of the condition. It also provides Atrial Fibrillation treatment algorithms and guidelines in the United States, Europe, and Japan.

Atrial Fibrillation Epidemiology

The Atrial Fibrillation epidemiology division provide insights about historical and current Atrial Fibrillation patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Atrial Fibrillation epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Atrial Fibrillation Epidemiology

The epidemiology segment also provides the Atrial Fibrillation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Atrial Fibrillation Drug Chapters

Drug chapter segment of the Atrial Fibrillation report encloses the detailed analysis of Atrial Fibrillation marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atrial Fibrillation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Atrial Fibrillation treatment.

Atrial Fibrillation Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Atrial Fibrillation treatment.

Atrial Fibrillation Market Outlook

The Atrial Fibrillation market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Atrial Fibrillation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Atrial Fibrillation market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Atrial Fibrillation market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Atrial Fibrillation market in 7MM.

The United States Market Outlook

This section provides the total Atrial Fibrillation market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Atrial Fibrillation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Atrial Fibrillation market size and market size by therapies in Japan is also mentioned.

Atrial Fibrillation Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Atrial Fibrillation market or expected to get launched in the market during the study period 2020-2034. The analysis covers Atrial Fibrillation market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atrial Fibrillation Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Atrial Fibrillation key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Atrial Fibrillation emerging therapies.

Reimbursement Scenario in Atrial Fibrillation

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Atrial Fibrillation domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Atrial Fibrillation market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Atrial Fibrillation Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Atrial Fibrillation, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Atrial Fibrillation epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Atrial Fibrillation are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Atrial Fibrillation market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atrial Fibrillation market

Report Highlights:

  • In the coming years, Atrial Fibrillation market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Atrial Fibrillation. Launch of emerging therapies will significantly impact the Atrial Fibrillation market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atrial Fibrillation
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Atrial Fibrillation Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Atrial Fibrillation Pipeline Analysis
  • Atrial Fibrillation Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Atrial Fibrillation Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Atrial Fibrillation Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Atrial Fibrillation Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Atrial Fibrillation market share (%) distribution in 2020 and how it would look like in 2034?
  • What would be the Atrial Fibrillation total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Atrial Fibrillation market size during the forecast period (2024-2034)?
  • At what CAGR, the Atrial Fibrillation market is expected to grow in 7MM during the forecast period (2020-2034)?
  • What would be the Atrial Fibrillation market outlook across the 7MM during the forecast period (2020-2034)?
  • What would be the Atrial Fibrillation market growth till 2032, and what will be the resultant market Size in the year 2034?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Atrial Fibrillation?
  • What is the historical Atrial Fibrillation patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Atrial Fibrillation in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Atrial Fibrillation?
  • Out of all 7MM countries, which country would have the highest prevalent population of Atrial Fibrillation during the forecast period (2020-2034)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Atrial Fibrillation treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Atrial Fibrillation in the USA, Europe, and Japan?
  • What are the Atrial Fibrillation marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Atrial Fibrillation?
  • How many therapies are developed by each company for Atrial Fibrillation treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Atrial Fibrillation treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atrial Fibrillation and their status?
  • What are the key designations that have been granted for the emerging therapies for Atrial Fibrillation?
  • What are the global historical and forecasted market of Atrial Fibrillation?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Atrial Fibrillation market
  • To understand the future market competition in the Atrial Fibrillation market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation market
  • To understand the future market competition in the Atrial Fibrillation market

Table of Contents

1. Key Insights

2. Executive Summary of Atrial Fibrillation

3. Competitive Intelligence Analysis for Atrial Fibrillation

4. Atrial Fibrillation: Market Overview at a Glance

  • 4.1. Atrial Fibrillation Total Market Share (%) Distribution in 2020
  • 4.2. Atrial Fibrillation Total Market Share (%) Distribution in 2034

5. Atrial Fibrillation: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Atrial Fibrillation Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Atrial Fibrillation Epidemiology Scenario in the 7MM (2020-2034)
  • 7.4. United States Epidemiology
    • 7.4.1. Atrial Fibrillation Epidemiology Scenario in the United States (2020-2034)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Atrial Fibrillation Epidemiology Scenario in Germany (2020-2034)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Atrial Fibrillation Epidemiology Scenario in France (2020-2034)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Atrial Fibrillation Epidemiology Scenario in Italy (2020-2034)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Atrial Fibrillation Epidemiology Scenario in Spain (2020-2034)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Atrial Fibrillation Epidemiology Scenario in the United Kingdom (2020-2034)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Atrial Fibrillation Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Atrial Fibrillation Treatment and Management
  • 8.2. Atrial Fibrillation Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Atrial Fibrillation Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Atrial Fibrillation: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Atrial Fibrillation Market Size in 7MM
  • 13.3. Atrial Fibrillation Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Atrial Fibrillation Total Market Size in the United States
    • 15.1.2. Atrial Fibrillation Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Atrial Fibrillation Total Market Size in Germany
    • 15.3.2. Atrial Fibrillation Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Atrial Fibrillation Total Market Size in France
    • 15.4.2. Atrial Fibrillation Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Atrial Fibrillation Total Market Size in Italy
    • 15.5.2. Atrial Fibrillation Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Atrial Fibrillation Total Market Size in Spain
    • 15.6.2. Atrial Fibrillation Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Atrial Fibrillation Total Market Size in the United Kingdom
    • 15.7.2. Atrial Fibrillation Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Atrial Fibrillation Total Market Size in Japan
    • 15.8.3. Atrial Fibrillation Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Atrial Fibrillation

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

List of Tables

  • Table 1: 7MM Atrial Fibrillation Epidemiology (2020-2034)
  • Table 2: 7MM Atrial Fibrillation Diagnosed and Treatable Cases (2020-2034)
  • Table 3: Atrial Fibrillation Epidemiology in the United States (2020-2034)
  • Table 4: Atrial Fibrillation Diagnosed and Treatable Cases in the United States (2020-2034)
  • Table 5: Atrial Fibrillation Epidemiology in Germany (2020-2034)
  • Table 6: Atrial Fibrillation Diagnosed and Treatable Cases in Germany (2020-2034)
  • Table 7: Atrial Fibrillation Epidemiology in France (2020-2034)
  • Table 8: Atrial Fibrillation Diagnosed and Treatable Cases in France (2020-2034)
  • Table 9: Atrial Fibrillation Epidemiology in Italy (2020-2034)
  • Table 10: Atrial Fibrillation Diagnosed and Treatable Cases in Italy (2020-2034)
  • Table 11: Atrial Fibrillation Epidemiology in Spain (2020-2034)
  • Table 12: Atrial Fibrillation Diagnosed and Treatable Cases in Spain (2020-2034)
  • Table 13: Atrial Fibrillation Epidemiology in the UK (2020-2034)
  • Table 14: Atrial Fibrillation Diagnosed and Treatable Cases in the UK (2020-2034)
  • Table 15: Atrial Fibrillation Epidemiology in Japan (2020-2034)
  • Table 16: Atrial Fibrillation Diagnosed and Treatable Cases in Japan (2020-2034)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
  • Table 20: Region-wise Market Size in USD, Million (2020-2034)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
  • Table 22: United States Market Size in USD, Million (2020-2034)
  • Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
  • Table 24: Germany Market Size in USD, Million (2020-2034)
  • Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
  • Table 26: France Market Size in USD, Million (2020-2034)
  • Table 27: France Market Size by Therapy in USD, Million (2020-2034)
  • Table 28: Italy Market Size in USD, Million (2020-2034)
  • Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
  • Table 30: Spain Market Size in USD, Million (2020-2034)
  • Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
  • Table 32: United Kingdom Market Size in USD, Million (2020-2034)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
  • Table 34: Japan Market Size in USD, Million (2020-2034)
  • Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Atrial Fibrillation Epidemiology (2020-2034)
  • Figure 2: 7MM Atrial Fibrillation Diagnosed and Treatable Cases (2020-2034)
  • Figure 3: Atrial Fibrillation Epidemiology in the United States (2020-2034)
  • Figure 4: Atrial Fibrillation Diagnosed and Treatable Cases in the United States (2020-2034)
  • Figure 5: Atrial Fibrillation Epidemiology in Germany (2020-2034)
  • Figure 6: Atrial Fibrillation Diagnosed and Treatable Cases in Germany (2020-2034)
  • Figure 7: Atrial Fibrillation Epidemiology in France (2020-2034)
  • Figure 8: Atrial Fibrillation Diagnosed and Treatable Cases in France (2020-2034)
  • Figure 9: Atrial Fibrillation Epidemiology in Italy (2020-2034)
  • Figure 10: Atrial Fibrillation Diagnosed and Treatable Cases in Italy (2020-2034)
  • Figure 11: Atrial Fibrillation Epidemiology in Spain (2020-2034)
  • Figure 12: Atrial Fibrillation Diagnosed and Treatable Cases in Spain (2020-2034)
  • Figure 13: Atrial Fibrillation Epidemiology in the UK (2020-2034)
  • Figure 14: Atrial Fibrillation Diagnosed and Treatable Cases in the UK (2020-2034)
  • Figure 15: Atrial Fibrillation Epidemiology in Japan (2020-2034)
  • Figure 16: Atrial Fibrillation Diagnosed and Treatable Cases in Japan (2020-2034)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
  • Figure 20: Region-wise Market Size in USD, Million (2020-2034)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
  • Figure 22: United States Market Size in USD, Million (2020-2034)
  • Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
  • Figure 24: Germany Market Size in USD, Million (2020-2034)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
  • Figure 26: France Market Size in USD, Million (2020-2034)
  • Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
  • Figure 28: Italy Market Size in USD, Million (2020-2034)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
  • Figure 30: Spain Market Size in USD, Million (2020-2034)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
  • Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
  • Figure 34: Japan Market Size in USD, Million (2020-2034)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary